Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

On Friday, Anavex Life Sciences Corp (AVXL) stock saw a modest uptick, ending the day at $9.24 which represents a slight increase of $1.60 or 20.94% from the prior close of $7.64. The stock opened at ...

Data of Blarcamesine confirm upstream SIGMAR1 activationPresented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.15% of ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) and keeping the price ...

Patients are currently being dosed in Part B of the Phase 2 study which will investigate a longer treatment duration NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex” or ...

Here Are Other Stocks Moving In Monday's Mid-Day Session Avi Kapoor Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39% Anavex ...

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...

Missling, PhD, President and Chief Executive Officer of Anavex. “We believe the scalable and convenient features of blarcamesine could reduce crucial barriers within the currently complex ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company ...

The data were presented by Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of the Anavex Scientific Advisory Board at the Clinical Trials on Alzheimer ...